Search Results 3781-3790 of 24972 for oral

  1. 0.0. Target. 80.5%. Oral Cavity & Pharynx. 17.4. 0.0. Pancreas. 15.0. 9.1. Brain & ONS. 8.3. 7.0. County. 65.4%. Esophagus. 6.5. 4.8. Colorectal. Liver & Bile ...

  2. Oral Cavity & Pharynx. 0.3. 1.5. Target. 74.4%. Uncategorized. 0.0. 0.0. Data Sources: Incidence and Mortality from State Cancer Profiles (for FL, AZ, WI, IA.

  3. Oral Cavity & Pharynx. County. 65.6%. Ovary. 0.0. Colorectal. Pancreas. 0.0. 0.0. Adults aged 50-75 years who reported. State. Stomach. 0.0. 0.0. Thyroid. 0.0.

  4. Oral Cavity & Pharynx. 20.6 reported Mammogram in 2 years. Bladder. 15.1. 0.0. Leukemia. 12.5. 0.0. Target. 80.5%. Pancreas. Brain & ONS. Cervix. Esophagus.

  5. Steroid dosage risks and benefits when managing lupus nephritis - Mayo Clinic News Network

    ... oral steroids. "Steroids have been used for 75 years, but there was minimal evidence about dosing," says Dr. Duarte García. "This research provides ...

  6. Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission - Mayo Clinic

    Up to two regimens of therapy (conventional chemotherapy, antibody therapy, or an oral regimen) are allowed as long as a continuous response was ongoing ...

  7. A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients - Mayo Clinic

    Has WHO/ NYHA functional class II to IV symptoms. 7. If on PAH-specific background oral therapy, subject is on stable therapy with either an endothelin ...

  8. Barrett's Esophagus Clinical Trials - Mayo Clinic Research

    Will oral supplementation with Omega 3 free fatty acids in obese Barrett's esophagus subjects downregulate pro-neoplastic and pro-inflammatory pathways in ...

  9. Biomedical Engineering and Physiology - Tracks - Ph.D. Program in Biomedical Science - Mayo Clinic College of Medicine & Science

    Effective communication is an essential skill, and our curriculum is designed to develop and enhance both oral and written communication proficiency. You'll ...

  10. Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) - Mayo Clinic

    ... oral medications * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration ...